Oruka Therapeutics officer proposes $1.61M share sale

The proposed shares are tied to stock-option exercises over the next three months, with Morgan Stanley Smith Barney LLC listed as broker.

Rhea-AI Filing Summary

Oruka Therapeutics, Inc. (ORKA) officer Joana Goncalves reported a proposed sale of 21,000 common shares, with an aggregate market value of $1,610,280.00; Morgan Stanley Smith Barney LLC is listed as broker. The notice states that the securities to be sold were and will be received through stock-option exercises over the next three months. It also lists sales of 7,000 shares on September 15, 2026, for $643,507.20 and 7,000 shares on August 17, 2026, for $782,882.10; both are identified as 10b5-1 sales.

Key Figures

Proposed shares for sale: 21,000 common shares Aggregate market value: $1,610,280.00 Shares sold: 7,000 shares +3 more

6 metrics

Proposed shares for sale 21,000 common shares Proposed sale by Joana Goncalves

Aggregate market value $1,610,280.00 21,000 common shares proposed for sale

Shares sold 7,000 shares September 15, 2026; identified as a 10b5-1 sale

Sale value $643,507.20 Sale on September 15, 2026

Shares sold 7,000 shares August 17, 2026; identified as a 10b5-1 sale

Sale value $782,882.10 Sale on August 17, 2026

Key Terms

10b5-1 Sales, stock options, Rule 144

3 terms

10b5-1 Sales regulatory

"10b5-1 Sales for JOANA GONCALVES"

10b5-1 sales are pre-arranged stock-trading plans that let company insiders automatically buy or sell shares according to a fixed schedule or formula, even if they later learn confidential information. Think of it as setting up an automatic thermostat for trades: it creates a clear, documented path that can protect insiders from insider-trading accusations and gives investors a signal about predictable insider activity—though it can also simply be a way for insiders to diversify or raise cash.

stock options financial

"Exercise of Stock Options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ORKA shares did Joana Goncalves propose to sell?

Joana Goncalves, an officer of Oruka Therapeutics, reported a proposed sale of 21,000 common shares, with an aggregate market value of $1,610,280.00. Morgan Stanley Smith Barney LLC is listed as broker.

What ORKA stock-option and 10b5-1 sales did Joana Goncalves report?

The proposed shares were to be received through stock-option exercises over the next three months. The notice also lists sales of 7,000 shares on September 15, 2026, for $643,507.20 and 7,000 shares on August 17, 2026, for $782,882.10; both are identified as 10b5-1 sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 04:38 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:38 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001756991
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Oruka Therapeutics, Inc.
SEC File Number	000-22873
Address of Issuer	855 Oak Grove Avenue Suite 100 Menlo Park CALIFORNIA 94025
Phone	6506067910
Name of Person for Whose Account the Securities are To Be Sold	JOANA GONCALVES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	21000	1610280.00	66209699	10/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/15/2026	Exercise of Stock Options	Issuer			21000	10/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JOANA GONCALVES 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	09/15/2026	7000	643507.20
10b5-1 Sales for JOANA GONCALVES 855 Oak Grove Avenue Suite 100 Menlo Park CA 94025	Common	08/17/2026	7000	782882.10

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	10/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/19/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joana Goncalves
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)